Healthcare >> CEO Interviews >> June 10, 2022
Keith C. Valentine has served as Chief Executive Officer of SeaSpine Holdings, a publicly traded medical device company focused on spinal implants and orthobiologics, since May 2015, and as President since July 2015, and joined their board of directors in July 2015 after a successful spinout from Integra LifeSciences. Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive, Inc. from January 2007 to January 2015 and as President from December 2004 to January 2007, prior to which he served in various senior executive roles in marketing, development and operations since joining NuVasive in 2001. While at NuVasive, Mr. Valentine was an active supporter of the medical device industry as a board member of the California Healthcare Institute (CHI) and the Medical Device Manufacturers Association (MDMA). Previously, Mr. Valentine served as Vice President of Marketing at ORATEC Interventions, Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek, including Vice President of Marketing for the Rods Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing. Mr. Valentine currently serves on the board of directors of SI-BONE, Inc., a publicly traded medical device company focused on the treatment of musculoskeletal disorders of the sacro-pelvic anatomy and chairs its nominating and governance committee. Mr. Valentine received a BBA in Management and Biomedical Sciences from Western Michigan University. Profile
John J. Bostjancic has served as Chief Financial Officer of SeaSpine Holdings Corp. since March 2015, and in May 2022 Mr. Bostjancic was appointed to his expanded role of Chief Operating and Financial Officer. Prior to this, he served as Treasurer and Senior Vice President at SeaSpine. Previously Mr. Bostjancic served as acting Chief Financial Officer of the SeaSpine business within Integra LifeSciences Holdings Corporation since 2014 and prior to that he was Senior Vice President of global supply chain at Integra from 2012 to 2014. His responsibilities included global planning, kitting, distribution, logistics and customer service in the role, and he led the project team implementing the U.S. Food and Drug Administration’s “unique device identifier” rule in 2014. From 2008 until 2012 Mr. Bostjancic was senior vice president of financial planning and analysis at Integra. Since joining Integra in 1999 he held roles of increasing responsibility in the finance organization, including corporate controller from 2003 through 2006. Before joining Integra, from 1998 through 1999, Mr. Bostjancic was a manager in the accounting standards team at Merck & Co., Inc. Prior to that he worked in the business assurance organization at Price Waterhouse Coopers from 1993 through 1998. He received his B.S. in accounting from the College of New Jersey. Profile
Word count: 3,256
TWST: Could you provide a brief overview of the company, its history, and its goals and priorities?
Mr. Valentine: SeaSpine is a pure-play